[go: up one dir, main page]

CO5170461A1 - DERIVATIVES OF 1,5-BENZODIAZEPIN MIND, PHARMACEUTICAL COMPOSITION CONTAINING IT, PROCESS FOR ITS PREPARATION AND IMPROVED PROCESS FOR THE PREPARATION OF INTERMEDIARIES FOR THE DERIVED SISNTHESIS - Google Patents

DERIVATIVES OF 1,5-BENZODIAZEPIN MIND, PHARMACEUTICAL COMPOSITION CONTAINING IT, PROCESS FOR ITS PREPARATION AND IMPROVED PROCESS FOR THE PREPARATION OF INTERMEDIARIES FOR THE DERIVED SISNTHESIS

Info

Publication number
CO5170461A1
CO5170461A1 CO00031982A CO00031982A CO5170461A1 CO 5170461 A1 CO5170461 A1 CO 5170461A1 CO 00031982 A CO00031982 A CO 00031982A CO 00031982 A CO00031982 A CO 00031982A CO 5170461 A1 CO5170461 A1 CO 5170461A1
Authority
CO
Colombia
Prior art keywords
preparation
phenyl
formula
mfi
jpeg
Prior art date
Application number
CO00031982A
Other languages
Spanish (es)
Inventor
David Colclough
Ann Hodgson
Szewczyk Jerzy Ryszard
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9910366.5A external-priority patent/GB9910366D0/en
Priority claimed from GBGB0008179.4A external-priority patent/GB0008179D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO5170461A1 publication Critical patent/CO5170461A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/121,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El compuesto caracterizado porque es el ácido 3-{3-[1-(lsopropil-fenil-carbamoilmetil)-2,4-dioxo-5-fenil-2,3,4,5-tetrahidro-1H-benzo[b][1,4]diazepin-3-il]ureido}benzoico enantioméricamente enriquecido, o una sal o solvato farmacéuticamente aceptable del mismo.<EMI FILE="00031982_1" ID="1" IMF=JPEG >Un proceso para la preparación de un compuesto de conformidad con la reivindicación 1, caracterizado porque comprende:(a) la separación del 3-[3-[1-(lsopropil-fenil-carbamoilmetil)-2,4-dioxo-5-fenil-2,3,4,5-tetrahidro-1H-benzo[b][1,4] diazepin-3-il]benzoico racémico, por cromatografía de líquidos de alta resolución, quiral;(b) la reacción del enantiómero apropiado de la amina de fórmula (II),<EMI FILE="00031982_2" ID="2" IMF=JPEG >Con el isocianato de fórmula (III), imidazolida de fórmula (IV) o carbamato de fenilo opcionalmente substituido de fórmula (V), seguido de la eliminación del grupo protector carboxi, R.<EMI FILE="00031982_3" ID="3" IMF=JPEG >The compound characterized in that it is 3- {3- [1- (lsopropyl-phenyl-carbamoylmethyl) -2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo [b] [ 1,4] diazepin-3-yl] ureido} enantiomerically enriched benzoic, or a pharmaceutically acceptable salt or solvate thereof. <EMI FILE = "00031982_1" ID = "1" MFI = JPEG> A process for the preparation of a compound according to claim 1, characterized in that it comprises: (a) the separation of 3- [3- [1- (lsopropyl-phenyl-carbamoylmethyl) -2,4-dioxo-5-phenyl-2,3,4,5 racemic -trahydro-1H-benzo [b] [1,4] diazepin-3-yl] benzoic, by high performance liquid chromatography, chiral; (b) the reaction of the appropriate enantiomer of the amine of formula (II), <EMI FILE = "00031982_2" ID = "2" MFI = JPEG> With the isocyanate of formula (III), imidazolide of formula (IV) or optionally substituted phenyl carbamate of formula (V), followed by removal of the protective group carboxy, R. <EMI FILE = "00031982_3" ID = "3" MFI = JPEG>

CO00031982A 1999-05-06 2000-05-04 DERIVATIVES OF 1,5-BENZODIAZEPIN MIND, PHARMACEUTICAL COMPOSITION CONTAINING IT, PROCESS FOR ITS PREPARATION AND IMPROVED PROCESS FOR THE PREPARATION OF INTERMEDIARIES FOR THE DERIVED SISNTHESIS CO5170461A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9910366.5A GB9910366D0 (en) 1999-05-06 1999-05-06 1,5-Benzodiazepine Derivatives
GBGB0008179.4A GB0008179D0 (en) 2000-04-05 2000-04-05 Chemical process

Publications (1)

Publication Number Publication Date
CO5170461A1 true CO5170461A1 (en) 2002-06-27

Family

ID=26244033

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00031982A CO5170461A1 (en) 1999-05-06 2000-05-04 DERIVATIVES OF 1,5-BENZODIAZEPIN MIND, PHARMACEUTICAL COMPOSITION CONTAINING IT, PROCESS FOR ITS PREPARATION AND IMPROVED PROCESS FOR THE PREPARATION OF INTERMEDIARIES FOR THE DERIVED SISNTHESIS

Country Status (21)

Country Link
EP (1) EP1212305A2 (en)
JP (1) JP2002544200A (en)
KR (1) KR20020012567A (en)
CN (1) CN1161345C (en)
AR (1) AR022044A1 (en)
AU (1) AU4754800A (en)
BR (1) BR0010338A (en)
CA (1) CA2370801A1 (en)
CO (1) CO5170461A1 (en)
CZ (1) CZ20013988A3 (en)
HK (1) HK1046138A1 (en)
HU (1) HUP0201181A3 (en)
IL (1) IL146124A0 (en)
MX (1) MXPA01011267A (en)
MY (1) MY138319A (en)
NO (1) NO20015397L (en)
NZ (1) NZ515048A (en)
PE (1) PE20010110A1 (en)
PL (1) PL351546A1 (en)
TR (1) TR200103169T2 (en)
WO (1) WO2000068209A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035793A2 (en) * 2003-10-09 2005-04-21 Decode Genetics Ehf. Cckar markers and haplotypes associated with extreme weight conditions
JP4069159B2 (en) 2004-05-25 2008-04-02 ファイザー・プロダクツ・インク Tetraazabenzo [e] azulene derivatives and analogs thereof
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
BR112022017039A2 (en) 2020-02-28 2022-11-16 Kallyope Inc GPR40 AGONISTS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9307833D0 (en) * 1993-04-15 1993-06-02 Glaxo Inc Modulators of cholecystokinin and gastrin

Also Published As

Publication number Publication date
TR200103169T2 (en) 2002-04-22
WO2000068209A3 (en) 2001-03-01
MY138319A (en) 2009-05-29
BR0010338A (en) 2002-02-13
JP2002544200A (en) 2002-12-24
AU4754800A (en) 2000-11-21
AR022044A1 (en) 2002-09-04
HUP0201181A2 (en) 2002-12-28
CN1362949A (en) 2002-08-07
WO2000068209A2 (en) 2000-11-16
HUP0201181A3 (en) 2003-10-28
PL351546A1 (en) 2003-05-05
CA2370801A1 (en) 2000-11-16
MXPA01011267A (en) 2002-05-06
KR20020012567A (en) 2002-02-16
NO20015397D0 (en) 2001-11-05
NO20015397L (en) 2001-11-05
CN1161345C (en) 2004-08-11
HK1046138A1 (en) 2002-12-27
PE20010110A1 (en) 2001-03-05
EP1212305A2 (en) 2002-06-12
NZ515048A (en) 2004-01-30
CZ20013988A3 (en) 2002-02-13
IL146124A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
KR910006277A (en) N-substituted-4-pyrimidineamines and pyrimidinediamines, methods for their preparation and their use as medicaments
PT80913B (en) PROCESS FOR THE PREPARATION OF NEW CYANO-SUBSTITUTED COMPOUNDS
PT971878E (en) Amine compounds, their production and use as amyloid-beta production inhibitors
CO5690131A1 (en) DERIVATIVES OF ETER BIARILICO PRESENTING ACTIVITY AS INHIBITORS OF THE RECOVERY OF MONOAMINS FOR THE TREATMENT OF CNS DISORDERS
CO5070574A1 (en) DERIVED FROM PHENOXYACETIC ACID AND PHARMACEUTICAL COMPOSITION CONTAINING IT
DK0667852T3 (en) New 3,3-diphenylpropylamines as well as their use and preparation
BR9812944A (en) Bicyclic kinase inhibitors
CO5420196A1 (en) INHIBITING COMPOUNDS OF METALOPROTEASE BIDENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS FOR USE
BR0310077A (en) New compounds and their use
ES2130079A1 (en) AMINE RESOLUTION
MY133445A (en) 2-arylethyl-(piperidin-4-ylmethyl)amine derivetives
CO5070569A1 (en) COMPOUND OF AMINOAZOL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND MEDICINAL PRODUCT CONTAINING THEM
KR900004658A (en) Disubstituted benzylamine, preparation method thereof, use thereof as medicament and synthesis agent thereof
CO5140104A1 (en) MEVINOLINE DERIVATIVES AND PHARMACEUTICAL PREPARATION CONTAINING THEM
CO5170461A1 (en) DERIVATIVES OF 1,5-BENZODIAZEPIN MIND, PHARMACEUTICAL COMPOSITION CONTAINING IT, PROCESS FOR ITS PREPARATION AND IMPROVED PROCESS FOR THE PREPARATION OF INTERMEDIARIES FOR THE DERIVED SISNTHESIS
ES2216333T3 (en) DERIVATIVES OF SUBSTITUTED ISOQUINOLINE AND ITS USE AS ANTI-CONVERSION.
KR900011724A (en) Certain pyrrolylphenyl-substituted hydroxamic acid derivatives
BR9406897A (en) Tetrahydroisoquinoline compounds pharmaceutical compositions process of analgesia or treatment of psychoses parkinson&#39;s disease leschnyan syndrome disorder of lack of attention or cognitive damage or in suppression of drug addiction or tardive dyskinesia and use of a compound
PT1234818E (en) CALCIUM SALTS OF 1,5-BENZODIAZEPINE DERIVATIVES, PROCESS FOR PRODUCTION OF SALTS AND DRUGS THAT CONTAIN THEM
SE9103022L (en) NEW 5H-BENZODIAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCEDURES FOR PREPARING THESE
ES2086528T3 (en) NEW BICYCLE COMPOUNDS REPLACED WITH AMINO.
DE60038112T8 (en) PROCESS FOR PREPARING (1R, 2S, 4R) - (-) - 2 - [(2 &#39;- {N, N-DIMETHYLAMINO} -ETHOXY)] - 2- [PHENYL] -1,7,7-TRI- [ METHYL] -BICYCLO [2.2.1] HEPTAN AND ITS PHARMACEUTICALLY ACCEPTABLE ACID ADDITIONAL SALTS
AR026222A1 (en) COMPOUNDS DERIVED FROM ANTRANILIC ACID
FR2768734B1 (en) NOVEL TRICYCLIC COMPOUNDS, THEIR PREPARATION PROCESS AND INTERMEDIATES THEREOF, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR002772A1 (en) PROCEDURE FOR SEPARATING A RACEMATE OF (+ -) - (2R, 3R; 2S, 3S) -1-AZABICICLO- [2.2.2] OCTAN-3-AMINE, 2- (DIPHENYLMETHYL) -N - [[2-METOXY -5- (1-METHYL-ETHYL) PHENYL] METHYL], AND PROCEDURE FOR PREPARING AN ENANTIOMER (2S, 3S) OF 1-AZABICICLO- [2, .2.2] OCTAN-3-AMINE, 2- (DIPHENYL-METHYL) -N - [[2-METOXI-5- (1-METHYL-ETHL) -PHENYL] METHYL]

Legal Events

Date Code Title Description
FC Application refused